Vera Deneer is hospital pharmacist – clinical pharmacologist and associate professor at UMC Utrecht. She is associate professor of clinical pharmacology at the Utrecht Institute for Pharmaceutical Research (UIPS) at the Division of Pharmacoepidemiology and Clinical Pharmacology and vice chair of the Medicines Evaluation Board (CBG-MEB).

She received a PharmD form Utrecht University in 1991 and a PhD at Groningen University, The Netherlands, in 2003. Her PhD research project was on clinical pharmacology and pharmacokinetics of antiarrhythmic drugs in atrial fibrillation. She completed clinical training in hospital pharmacy in 1994, followed by training in clinical pharmacology which ended in 1998. From 1998 – 2017 she was head of the Pharmacogenetics, Pharmaceutical and Toxicological Laboratory at St. Antonius Hospital, Nieuwegein/Utrecht. Since 2017 she is employed as a hospital pharmacist – clinical pharmacologist by the University Medical Center Utrecht (UMC Utrecht) at the Department of Clinical Pharmacy. Her clinical interests are in the field of cardiovascular disease, lung disease, including lung cancer, the implementation of pharmacogenetics in daily clinical practice, drug safety and medication management.

In 2015 she became a member of the Medicines Evaluation Board (MEB-CBG) and in 2019 she was appointed vice chair. Furthermore, she is chair of the Dutch Pharmacogenetics Working Group (DPWG). From 2012 – 2017 she was chair of MEC-U, a medical research ethics committee. She also serves either as a chair or member, on several national and hospital committees in the field of pharmacotherapy, drug safety.

Her research is on personalised medicine by studying the influence of biomarkers such as genetic variants, patient characteristics and clinical parameters on the effects of drugs in terms of efficacy and safety. She studies biomarker guided drug treatment strategies to optimise drug treatment of individual patients with the main focus on cardiovascular disease, lung cancer, immune mediated inflammatory diseases. The ultimate goal is to improve beneficial effects and patient outcomes and lowering the risk of developing adverse drug reactions, toxicity. Pharmacists have a role in optimizing drug treatment in daily clinical practice. She is the principal investigator of several research projects some of them funded by The Netherlands Organisation for Health Research and Development.